Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)

Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head & Neck Surgery at Stanford University.

开始日期2026-07-01

申办/合作机构

Stanford University

IRCT20150303021315N41

/ Recruiting临床3期

A phase III, randomized, two-armed, double-blind, single-center, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of Galcanezumab (CinnaGen Co.) versus Emgality® (Eli Lilly Co.) in adults with treatment-resistant migraine

开始日期2026-02-21

申办/合作机构

CinnaGen Co.

NCT07323927

/ Recruiting早期临床1期IIT

An Investigator Initiated Trial Evaluating the Therapeutic Efficacy of Galcanezumab in Patients With Alzheimer's Disease

This single-arm, open-label clinical study systematically evaluates the efficacy and safety of Galcanezumab in patients with mild-to-moderate Alzheimer's disease (AD). Eligible participants who provided written informed consent were screened and enrolled to receive Galcanezumab treatment. The therapeutic regimen involved subcutaneous administration of Galcanezumab with an initial 240 mg loading dose followed by 120 mg maintenance doses every four weeks for six total administrations over a 24-week treatment period. All study procedures were conducted at the Advanced Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University. Comprehensive data collection and clinical assessments were performed at baseline (pre-treatment), week 12 (Visit 3), week 24 (Visit 4), and week 36 (Visit 5, 12 weeks after the final dose) to evaluate treatment outcomes and safety profiles. The study design incorporates standardized clinical trial methodology while maintaining the flexibility required for exploratory therapeutic evaluation.

开始日期2025-08-01

申办/合作机构

首都医科大学宣武医院

100 项与加卡奈珠单抗相关的临床结果

登录后查看更多信息

100 项与加卡奈珠单抗相关的转化医学

登录后查看更多信息

100 项与加卡奈珠单抗相关的专利（医药）

登录后查看更多信息

518

项与加卡奈珠单抗相关的文献（医药）

2026-08-01·Pain and Therapy

Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study

Article

作者: Miki, Yasuhiro ; Hashimoto, Chie ; Takizawa, Tsubasa ; Ueda, Kaname ; Takemura, Ryo

INTRODUCTION:

Understanding real-world calcitonin gene-related peptide monoclonal antibodies' (CGRP mAbs) use in patients with migraine is necessary to potentially guide treatment strategies.

METHODS:

This retrospective cohort study analyzed administrative claims data from the IQVIA claims data for Japan. It included CGRP mAb-naïve individuals with confirmed migraine diagnosis and ≥ 1 CGRP mAb prescription (January 2021-June 2023). Index date was the first CGRP mAb prescription. Patient characteristics, treatment patterns, adherence (proportion of days covered ≥ 0.80), persistence, and migraine-related direct costs were assessed. Persistence was measured as the proportion of patients continuing treatment for ≥ 3 or ≥ 6 months (≤ 90-day gap between fills). Factors predicting adherence to CGRP mAb treatment were assessed using multivariate logistic regression. Subgroup analyses were conducted for galcanezumab users.

RESULTS:

Of the 1781 patients included (mean age 41.8 years [standard deviation, SD 10.3]; 79.3% female patients), 55.0% received galcanezumab, followed by fremanezumab (29.7%), and erenumab (15.3%). The prescription rates of concomitant acute and oral preventive medications were 86.1% and 51.3%, respectively, in the first 3 months after initiating CGRP mAb treatment but numerically decreased to 49.8% and 22.5%, respectively, in the fourth to sixth month. The index CGRP mAb persistence rates were 91.9% for ≥ 3 months and 76.9% for ≥ 6 months, and adherence rate was 51.7%. Multiple positive and negative predictors of adherence to CGRP mAbs were observed. Index to 3 months after initiating index CGRP mAbs, the median average monthly migraine-related costs were JPY 75,320 (Q1, Q3 61,593, 89,843) (USD 592), and non-CGRP mAb migraine-related costs were JPY 15,702 (Q1, Q3 8845, 27,848) (USD 123). These costs tended to reduce or plateau for up to 12 months thereafter. The galcanezumab subgroup showed a similar trend.

CONCLUSIONS:

CGRP mAb adherence and ≥ 6 months persistence rates were 51.7% and 76.9%, respectively, in CGRP mAb-initiating adults with migraine in Japan. During CGRP mAb treatment, acute and oral preventive medication prescription rates appeared to reduce, while direct costs initially increased but appeared to reduce from the post-initiation peak and plateau over time, although the underlying reasons could not be determined from claims data.

2026-07-03·Expert Review of Neurotherapeutics

Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache

Review

作者: Villalón, Carlos M. ; González-Hernández, Abimael ; Ferrusca, José D.

INTRODUCTION:

The introduction of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has revolutionized migraine treatment. In this regard, galcanezumab, a humanized immunoglobulin G4 (IgG4) that binds the CGRP molecule, has rapid onset of action, monthly dosing, and favorable pharmacokinetics.

AREAS COVERED:

This review, which draws upon electronic databases such as PubMed, Web of Science, FDA, and EMA, provides a comprehensive summary of galcanezumab for migraine prophylaxis. It covers the drug's mechanism of action, its clinical efficacy in episodic migraine, and its potential benefits in episodic cluster headache and medication-overuse headache. It also provides an overall safety profile based on clinical trials and real-world studies.

EXPERT OPINION:

Galcanezumab is a cornerstone preventive therapy with consistent efficacy, favorable tolerability, and convenient dosing. Key unmet needs include identifying biomarkers to predict responders, addressing access and cost barriers, optimizing evaluation windows for late-responders, and expanding the evidence base for special populations (pediatrics, pregnancy, and vascular comorbidities). Future studies should refine patient selection and explore complementary targets for non-responders.

2026-07-01·HEADACHE

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Article

作者: Cristina Tassorelli MD, PhD ; Carlos Vallarino PhD ; Shivang Joshi MD, MPH, PRh, FAHS ; Rebecca L. Robinson MS ; Manjit Matharu BSc, MBChB, FRCP, PhD ; Maurice Vincent MD, PhD ; Taoufik Alsaadi MD ; Lars Viktrup MD, PhD

Abstract:

Objective:

To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.

Background:

Multiple TOMP medications (within classes of beta‐blockers, anticonvulsants, tricyclic antidepressants, angiotensin II receptor antagonists, and calcium channel blockers) originally developed to treat other conditions are used for migraine prevention. In a recent real‐world analysis comparing galcanezumab with a broader classification of TOMP, a significantly greater proportion of patients treated with galcanezumab achieved a clinically meaningful response at 3 months (reduction from baseline in monthly migraine headache days) (46.6% vs. 34.5%, p < 0.001). Treatment selection is often individualized based on patients' historical and current clinical profiles, preferences, and comorbid conditions. Comparing the real‐world effectiveness of galcanezumab with specific TOMP using stringent criteria based on established efficacy at a global level will provide additional insights.

Methods:

The TRIUMPH (preventive TReatment of mIgraine: oUtcoMes for Patients in real‐world Healthcare systems) study is an ongoing, international, prospective observational cohort study comparing the effectiveness of galcanezumab with other preventives (EUPAS33068). A priori sample size was achieved, and interim data (Feb 25, 2020, to Feb 9, 2023) were analyzed. The current analysis compared patients with migraine initiating galcanezumab versus the TOMP efficacy subset (drugs with established/probable efficacy based on the 2021 American Headache Society consensus statement incorporating the American Academy of Neurology classification of evidence and consistent with the European Headache Federation/European Academy of Neurology and Japanese Society of Neurology/Japanese Headache Society). Galcanezumab was also compared with the most frequently used individual TOMP drugs in the TRIUMPH study. Reduction in monthly migraine headache days (≥50%: episodic migraine, ≥30%: chronic migraine) from baseline to 3 months was assessed after adjusting for baseline cohort differences.

Results:

At the time of this analysis, 2398 patients from the United States, Japan, Germany, Italy, the United Kingdom, Spain, and the United Arab Emirates had completed baseline assessments. Topiramate ( n = 343) and amitriptyline ( n = 240) were the most frequently used TOMP drugs. At 3 months, the galcanezumab cohort ( n = 1065) had a greater weighted proportion of responders versus the TOMP efficacy subset ( n = 916) (48.3% [95% confidence interval [CI]: 45.1%, 51.6%] vs. 35.9% [95% CI: 32.6%, 39.3%]; p < 0.001), topiramate ( n = 343) (48.8% [95% CI: 45.7%, 51.9%] vs. 37.2% [95% CI: 31.2%, 43.7%]), and amitriptyline ( n = 240) (49.7% [95% CI: 46.6%, 52.8%] vs. 23.3% [95% CI: 17.5%, 30.4%]) cohorts.

Conclusion:

In this real‐world study, galcanezumab induced a clinically meaningful reduction in migraine headache days in a higher proportion of patients than TOMP medications classified as efficacious, including topiramate and amitriptyline.

Trial Registration Number:

EUPAS33068.

234

项与加卡奈珠单抗相关的新闻（医药）

2026-09-11

·贝壳社

首个III期阳性，艾伯维有望再下一城

9月10日，艾伯维宣布其降钙素基因相关肽（CGRP）受体拮抗剂atogepant用于成人月经性偏头痛预防性治疗的III期LUNA研究取得积极的顶线结果。月经性偏头痛包括单纯月经性偏头痛和月经相关性偏头痛，发作集中在月经期前后这一生物学易感窗口。在CaMEO-I国际研究中，66%的女性偏头痛患者报告了月经期相关的偏头痛发作。其中，LUNA是一项III期、多中心、随机、双盲、安慰剂对照研究，旨在评估atogepant用于月经性偏头痛预防性治疗的疗效、安全性和耐受性。研究在全球（欧洲和亚洲）多个中心入组了468名患有单纯月经性偏头痛或月经相关性偏头痛（伴或不伴先兆）的成年女性受试者，诊断标准参照国际头痛学会《头痛疾患国际分类》第三版（ICHD-3）。主要终点评估双盲治疗期跨越三个月经周期的围月经期偏头痛天数较基线的变化。次要终点包括头痛天数、中重度头痛天数、急性用药天数、中重度偏头痛天数、应答率、功能残疾和认知功能。目前，atogepant在III期LUNA研究中达成主要终点及全部序贯次要终点，该研究评估了atogepant在三个连续月经周期中、从月经开始前3天起连续给药7天的疗效。atogepant达到了主要终点，在双盲治疗期跨越三个月经周期的围月经期偏头痛天数变化方面，atogepant组的平均减少天数显著优于安慰剂组。具体而言，atogepant组平均减少1.20天，安慰剂组减少0.40天，较安慰剂多减少0.80天（p<0.0001）。在全部八项序贯次要终点上，atogepant较安慰剂均显示出统计学显著且具有临床意义的改善（p<0.0001），包括头痛负担、急性用药天数、功能残疾、认知功能和应答率等指标。安全性结果与atogepant已知的安全性特征一致，未观察到新的安全性信号。艾伯维免疫学、神经科学、眼科及专科药物全球开发高级副总裁Primal Kaur博士表示："LUNA研究的III期阳性结果对于月经性偏头痛患者而言是一项重要进展。月经性偏头痛发作往往更严重、持续时间更长，严重影响日常生活。这些数据使我们离实现为罹患这一疾病的女性带来潜在的治疗选择目标更近一步。" LUNA是首个针对月经性偏头痛，报告出积极结果的CGRP靶向治疗研究，满足了女性的重要未满足需求。艾伯维计划向全球卫生监管机构提交上述数据，并在未来医学会议上展示相关研究结果。据悉，atogepant是一种口服给药的降钙素基因相关肽（CGRP）受体拮抗剂，属于靶向偏头痛相关通路的药物类别。在预防性治疗中，atogepant每日给药一次；在急性治疗中按需给药。atogepant目前已在全球60个国家获批。在普通偏头痛预防领域，atogepant面临来自同类CGRP受体拮抗剂（如rimegepant、ubrogepant）以及CGRP单抗（如erenumab、fremanezumab、galcanezumab、eptinezumab）的竞争。在这个市场中，几个趋势正在同时发生：一是头部企业正在进行CGRP药物从预防性治疗向急性治疗的双线布局；二是适应症细分（如慢性偏头痛、月经性偏头痛、伴有先兆的偏头痛等）成为差异化竞争的重要手段；三是给药方式的创新（口服、皮下注射、静脉输注）在塑造不同产品的市场定位。 atogepant是FDA批准的首个专门为预防性治疗偏头痛而开发的口服速释片，此次在LUNA研究中的阳性结果，如果后续顺利推进至获批，将为艾伯维在偏头痛领域的产品矩阵增加一个新的适应症维度。往期推荐 1 贝壳观察：行业观察 2 贝壳时刻 *声明：本文仅用于分享，不构成任何投资建议，且非治疗方案推荐。素材来源官方媒体/网络新闻关于贝壳社贝壳社（Bioclub）是行业领先的医健创新创业服务平台，构建了"产业空间+ 创业培育+投资孵化+资本赋能"四位一体为核心，叠加"品牌媒体+医学成果转化"，形成"4+2"全链路赋能业务体系，通过深度挖掘全球范围内的高成长项目、精准匹配产业资源及全球生态网络，覆盖企业从孵化培育到加速发展的全周期赋能服务。目前已在上海、杭州、香港、澳洲墨尔本四大核心城市设立办公室与服务中心，国际化布局完善，积极推进境外业务深耕拓展，搭建成熟全球化服务网络，全方位助力医健企业实现跨境发展与国际化落地。贝壳社以加速科学技术成果转化与产业升级为目标，致力于成为医健领域的孵化器、加速器、连接器。

2026-09-10

·allsci.com

AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial

Atogepant (Qulipta/Aquipta) met the primary endpoint and all eight ranked secondary endpoints in the Phase III LUNA trial evaluating preventive treatment of menstrual migraine, AbbVie (NYSE: ABBV) reported. No treatment is currently approved specifically for menstrual migraine, meaning the data could support a dedicated menstrual-migraine indication. The LUNA study is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 468 adult women with pure menstrual migraine or menstrually-related migraine across sites in Europe and Asia. The dosing regimen differed from atogepant's approved once-daily preventive use: participants took the drug for seven consecutive days starting three days before the onset of menses, repeated over three menstrual cycles. The primary endpoint was the change from baseline in migraine days during the perimenstrual period, averaged across those three cycles. Atogepant produced a mean reduction of 1.20 migraine days versus 0.40 days with placebo — a difference of 0.80 days (p<0.0001). All eight ranked secondary endpoints, covering headache burden, acute medication use, functional disability, cognitive function, and responder rates, also reached statistical significance (p<0.0001). Safety was consistent with atogepant's established profile, with no new signals identified. Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP from binding to its receptor, interrupting a signaling pathway elevated during migraine attacks. The drug is already approved in the US for both episodic and chronic migraine prevention under the brand name Qulipta, and in June 2026 received European Commission approval for the acute treatment of migraine in adults as Aquipta — its second EU indication. The LUNA data extend atogepant into a distinct patient subpopulation that existing CGRP-targeted therapies have not been specifically studied in or approved for. Anti-CGRP monoclonal antibodies such as Amgen's Aimovig (erenumab) and Eli Lilly's Emgality (galcanezumab) have been evaluated in post-hoc analyses of women with menstrual migraine history, but none has pursued a dedicated regulatory indication. The LUNA trial's prospective, indication-specific design positions atogepant differently from those agents in this setting. AbbVie said it plans to submit the LUNA data to health authorities globally and present full results at a future medical congress. The specific dose used in LUNA was not disclosed in the topline release. Access the AllSci platform to explore the science behind the news. Spot something wrong? Report an issue with this article

临床3期临床结果上市批准

2026-09-01

·今日头条

改善失眠全攻略：药物、食材、保健品，到底该怎么选？

深夜，你又一次在黑暗中睁着眼睛，数羊、刷手机、翻来覆去；你的大脑开了台不听指挥的放映机，白天开会的画面、明天的待办事项、五年前的尴尬瞬间轮番上演。好不容易熬到凌晨三点睡着，闹钟一响，整个人像被车碾过。这不是矫情——《中国睡眠健康调查报告》显示，我国近半数成年人正在被入睡困难、睡眠浅、早醒、昼夜节律紊乱等问题困扰。睡不着、睡不好、睡不醒，正悄悄拖垮一个人的情绪、记忆、免疫力和心血管健康。好消息是，失眠并非"无解"，它的改善路径其实非常清晰——药物治病、食品调理、保健品辅助，三者各司其职，不可互相替代。一、临床常用的失眠药物：处方药，需要在医生指导下使用临床常用的助眠处方药主要分为五大类，各有明确的适用人群、优势与限制。几点共性提醒：疗程尽可能短，一般不超过4周；停药要逐步减量，避免反跳性失眠；老年人、孕产妇、青少年属于特殊人群，任何安眠药都必须在医生指导下使用，不建议自行去药店购买或从网上代购。二、正在临床研究中的失眠创新药除了已上市的药物，科研机构和企业正在从三个方向开发新一代的助眠方案。 1. 小分子化学药：从"强制抑制"走向"调节觉醒" 双重食欲素受体拮抗剂（DORA）是当前最受关注的赛道。食欲素是大脑中负责"维持清醒"的神经肽，DORA通过精准阻断食欲素与其受体的结合，让大脑的觉醒驱动力自然下降，从而接近生理状态地入睡，并完整保留深睡眠和快速眼动睡眠结构。达利雷生：2022年《柳叶刀·神经病学》发表的两项Ⅲ期临床试验纳入了17个国家156个中心的1854名失眠患者，结果显示50mg和25mg剂量均能显著减少入睡后觉醒时间和睡眠潜伏期，50mg剂量还能改善患者自我报告的总睡眠时间和日间嗜睡评分，且无明显次日残留效应。该药已于2024年在中国提交上市申请。来那氯生：Ⅲ期临床试验显示，5mg和10mg剂量在治疗1个月即显著改善失眠严重程度指数（ISI）和疲劳严重程度量表（FSS）评分，且改善效果持续到6个月。 Seltorexant：一种高选择性食欲素2受体拮抗剂，2025年9月公布的Ⅲ期MDD3005研究显示，作为重度抑郁伴失眠患者的辅助治疗，26周应答率达57.4%（对照组喹硫平缓释片为53.4%），嗜睡发生率仅为对照组的1/4（6% vs 24%），平均体重增加0.5kg（对照组2.1kg），耐受性优势明显。地达西尼：我国已上市的新型苯二氮䓬受体激动剂，达峰时间约1小时，半衰期约4小时，可缩短入睡时间、增加总睡眠时间并改善日间疲劳。 2. 生物药：从源头调节与睡眠相关的生理通路生物药在失眠领域尚处于早期探索阶段，但已经出现了一些值得关注的线索： ABCL635：一种神经激肽3受体（NK3R）拮抗剂抗体，2026年8月公布的Ⅱ期临床试验显示，单次皮下注射即可显著改善更年期女性的血管舒缩症状，同时显著改善睡眠质量，耐受性良好。抗CGRP单克隆抗体：原本用于偏头痛预防，多项观察性研究发现，使用依瑞奈尤单抗、加卡奈珠单抗等药物后，偏头痛患者的匹兹堡睡眠质量指数（PSQI）显著改善，日间嗜睡也有所下降，提示通过控制共病疾病可能间接改善睡眠。度匹鲁单抗：IL-4受体α拮抗剂，一项纳入7项研究、2164例慢性鼻窦炎伴鼻息肉患者的系统评价显示，该药可显著改善患者的睡眠质量指标。 δ睡眠诱导肽（DSIP）：一种天然神经肽，一项4周随机对照试验显示鼻喷给药可使慢波睡眠增加22%、睡眠效率从78%提升至86%，但证据等级较低，仍需更大规模研究验证。 3. 中药：循证研究持续推进中药在失眠治疗上有悠久的临床应用基础，近年也积累了不少RCT和Meta分析证据，并被《中成药治疗失眠临床应用指南（2023年）》收录推荐：乌灵胶囊：源于珍稀药用真菌乌灵参，现代药理研究显示其可增加脑内GABA合成、提高GABA受体活性，从而发挥镇静安神作用。Meta分析显示，单用或联合西药治疗失眠的疗效优于常规西药，能更显著改善睡眠质量，且不良反应发生率更低。舒眠胶囊：多导睡眠监测显示可延长总睡眠时间和N2期睡眠，6项RCT荟萃分析显示其不良反应发生率低于镇静催眠药。枣仁安神胶囊：多项RCT显示其疗效与镇静催眠药相当，但不良反应更少，尤其适合老年人群。百乐眠胶囊、参松养心胶囊等也在各自适应证中显示出改善睡眠质量的作用。需要说明的是，目前尚无任何一种创新药或中药获得"根治失眠"的监管批准，临床研究数据反映的是平均疗效，个体差异依然存在。三、药食同源食材：日常餐桌上的温和调理国家卫健委公布的"药食同源"目录中，有几味食材被广泛用于日常睡眠调理。它们作用温和，适合日常使用，但不能替代药物治疗中重度失眠。几个日常小贴士：晚餐可适量选择小米、香蕉、牛奶等富含色氨酸的食物，帮助身体合成褪黑素前体；晚餐不宜过饱，睡前2小时避免浓茶、咖啡、酒精；再配合每天30分钟舒缓运动如散步、八段锦，调理效果会更稳定。需要提醒的是，药食同源食材的作用是长期、温和、辅助的，不要期待一两周就"药到病除"，更不要为了"效果更好"就大量堆叠——任何食材吃多了都可能带来消化负担或体质偏颇。四、助眠功能性保健品：辅助改善，不是"特效药" 市面上助眠保健品五花八门，核心成分主要有以下几类。选购避坑指南认准"蓝帽子"：在国内销售的褪黑素类产品必须有国家市场监管总局的保健食品备案标志，可在"特殊食品信息查询平台"核验备案号；跨境产品属于普通食品，依法不允许宣称任何保健功能。警惕"高剂量=高效果"的误导：褪黑素1-3mg已经够用，超过10mg不仅不会增强效果，反而增加次日头晕、头痛风险。不要把保健品当药吃：膳食补充剂本质是"辅助调理"，对中重度失眠无效；市面上有些产品宣称"7天改善失眠"“无依赖无副作用”，超出了保健食品合法的功能宣称范围。看成分配方而非价格噱头：低剂量褪黑素+维生素B6/GABA/茶氨酸的复配方案，比单一高剂量褪黑素更贴合日常睡眠调理需求。特殊人群慎用：未成年人、孕产妇、哺乳期女性、甲亢患者、自身免疫疾病患者、长期服用多种药物人群，使用前建议咨询执业医师。警惕"品牌内部观察数据"：某些跨境产品引用的"志愿者体验数据"只是品牌内部记录，不能等同于临床证据。五、三者关系一句话理清理解了三者的定位差异，才能根据自己的情况做对选择：药物治病：由医生处方，针对已达疾病程度的中重度或慢性失眠，有明确适应证、剂量和疗程控制。食品日常调理：药食同源食材融入一日三餐，适合健康人群日常养生或轻度睡眠波动者长期温和调理。保健品辅助改善：介于食品与药物之间，适合节律紊乱、轻度睡眠浅等特定场景的短期辅助，不能替代治疗。三层之间不是"越贵越好"，也不是"越天然越安全"，而是"越对症越好"。保健品不能当药吃，食品也不能包治失眠，药物更不能自己随便买来长期吃。六、给读者的实用建议先判断是否真的失眠：偶尔熬夜、换环境睡不着不等于失眠；临床上要求症状每周至少3次、持续一段时间并影响白天状态，才需要干预。首选非药物手段：国际公认的失眠一线治疗其实是失眠认知行为疗法（CBT-I），通过调整睡眠习惯和认知来改善睡眠，效果持久且无副作用。就医是明智选择，不是示弱：如果失眠已经持续数周以上、影响白天工作情绪，或伴随打鼾、呼吸暂停、情绪持续低落，应到正规医院睡眠门诊或精神心理科就诊，查明原因比急着买药更重要。建立"睡眠卫生"基础盘：无论用什么方式改善睡眠，规律作息、卧室避光、睡前1小时远离屏幕、避免睡前饮酒和咖啡因，都是不可省略的"地基"。理性看待新药和新技术：处于临床研究阶段的创新药为未来提供了更多选择，但任何新方案都要经过严格审批才能上市，患者能接触到的仍以现有获批药物和成熟调理方式为主。不以"睡够8小时"作为唯一标准：每个人的睡眠需求不同，白天精神好、不困倦，即使睡得短一些，也未必是问题；反过来，睡得长但白天昏昏沉沉，也值得排查。睡眠是健康的基石，但它也是可以被科学理解和管理的过程。与其在深夜独自焦虑，不如从今天开始把作息、饮食、运动这三件事先理顺；如果问题持续，就交给专业医生评估。把失眠当作一个需要被认真对待的信号，而不是一个需要被战胜的敌人，往往反而是改善的开始。

100 项与加卡奈珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10936	加卡奈珠单抗	N02CD02	DB14042

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
丛集性头痛	美国	Eli Lilly & Co.	2019-06-04
偏头痛	美国	Eli Lilly & Co.	2018-09-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
无先兆偏头痛	临床3期	美国	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	日本	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	丹麦	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	德国	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	印度	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	意大利	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	墨西哥	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	荷兰	Eli Lilly & Co.	2018-03-14
无先兆偏头痛	临床3期	西班牙	Eli Lilly & Co.	2018-03-14
膝关节炎	临床2期	美国	Eli Lilly & Co.	2014-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAN2026	N/A	偏头痛	17,220	Erenumab	鬱膚選淵築繭膚觸鑰選(壓艱鹹廠簾淵積選製築) = 齋艱願壓淵蓋積遞醖顧夢憲鬱壓積觸餘網糧顧 (衊窪繭醖觸淵顧製壓獵, 0.96 ~ 1.21) 更多	积极	2026-04-25
				Fremanezumab	齋憲壓鏇艱繭襯憲艱鑰(網鏇鹽壓遞鏇繭廠鹽築) = 觸膚獵淵網壓衊糧憲糧網憲選憲觸築簾繭壓憲 (願鑰憲繭齋簾鹹餘簾窪 ) 更多
NCT04158752 (CTgov)	临床4期	神经原性感染 \| 小纤维神经病变 \| 三叉神经痛 ... 更多	26	Galcanezumab	遞繭憲鑰觸鑰繭鹹醖廠(醖齋觸鹽鏇鬱遞憲鹽遞) = 網齋構廠齋鹹製鹹衊淵壓鬱襯簾膚製顧憲淵製 (艱夢夢衊獵鏇願鹹鬱醖, 0.2663) 更多	-	2026-02-02
AAN2025	N/A	丛集性头痛	258	Galcanezumab 240-300 mg	鹹醖鬱製窪衊鑰築膚觸(繭構範壓鑰遞夢糧願壓) = 網壓鹹淵範壓艱顧餘衊醖醖鑰憲膚簾淵鏇繭簾 (鬱襯壓襯壓夢顧餘構衊, 45.8 ~ 87.4) 更多	积极	2025-04-07
NCT02614261 (REGAIN, Pubmed \| J Headache Pain)	临床3期	偏头痛	-	Placebo	蓋壓窪鑰衊餘蓋夢觸醖(夢襯淵製觸鏇膚獵壓蓋) = 選衊鹽鬱製築鹽窪觸鏇膚鹹簾構鏇鑰製鏇壓淵 (憲鬱餘鬱廠簾製範網齋 )	积极	2025-02-03
				Galcanezumab 120 mg with 240-mg loading dose	蓋壓窪鑰衊餘蓋夢觸醖(夢襯淵製觸鏇膚獵壓蓋) = 構糧鑰醖構衊觸選鬱膚膚鹹簾構鏇鑰製鏇壓淵 (憲鬱餘鬱廠簾製範網齋 ) 更多
NCT04417361 (CTgov)	临床2期	偏头痛 \| 无先兆偏头痛	40	Galcanezumab Prefilled Syringe (Galcanezumab)	廠築壓簾鑰構網壓鬱構(構醖夢糧憲遞構範憲鏇) = 齋淵範觸網壓鬱觸夢獵積簾齋獵醖齋構獵膚蓋 (鬱簾網願蓋壓鹹獵積願, 16.1) 更多	-	2024-12-10
				Placebo (Placebo)	廠築壓簾鑰構網壓鬱構(構醖夢糧憲遞構範憲鏇) = 遞淵壓鏇齋廠簾積齋積積簾齋獵醖齋構獵膚蓋 (鬱簾網願蓋壓鹹獵積願, 17.3) 更多
INVESTMENT (Pubmed \| Headache)	N/A	偏头痛	40	Galcanezumab	壓鬱積顧壓簾鹽積憲構(齋廠餘憲獵淵願齋顧觸) = 夢壓艱獵膚鑰糧憲選憲醖齋蓋觸鏇願觸獵簾鬱 (艱網衊鏇餘蓋鏇獵鑰製, 7.3) 更多	积极	2024-11-01
				Placebo	壓鬱積顧壓簾鹽積憲構(齋廠餘憲獵淵願齋顧觸) = 鹹鬱築窪襯窪膚襯蓋壓醖齋蓋觸鏇願觸獵簾鬱 (艱網衊鏇餘蓋鏇獵鑰製, 11.2) 更多
NCT05127486 (CHALLENGE-MIG, CTgov)	临床4期	偏头痛	580	Placebo+Galcanezumab (Galcanezumab)	鬱鬱鏇壓窪顧鏇築鬱網 = 糧簾繭齋鏇鏇憲糧築鏇鹽網夢遞餘壓簾鹽壓鹹 (獵遞鏇遞憲遞襯襯築淵, 觸餘願鹽醖膚艱鑰鹹憲 ~ 餘餘糧簾憲鬱積蓋憲遞) 更多	-	2024-06-18
				Placebo+Rimegepant (Rimegepant)	鬱鬱鏇壓窪顧鏇築鬱網 = 淵壓鏇構夢襯構廠蓋艱鹽網夢遞餘壓簾鹽壓鹹 (獵遞鏇遞憲遞襯襯築淵, 築觸選鏇蓋顧憲網淵顧 ~ 製鬱衊壓構淵簾鹹艱獵) 更多
NCT02959177 \| NCT02959190 (Pubmed \| Neurol Ther) 人工标引	临床2期	偏头痛	406	galcanezumab 120 mg	鹹窪顧淵遞範鹹廠壓鏇(廠選遞鹽艱願衊鹽艱廠) = 襯鑰餘鹽構鬱壓淵糧鬱鹽製醖壓醖願積鏇積憲 (艱網膚願鏇構鬱淵獵顧, 4.64) 更多	积极	2024-06-01
				galcanezumab 240 mg	鹹窪顧淵遞範鹹廠壓鏇(獵壓糧衊構襯積蓋憲廠) = 願鑰壓廠鑰構構鏇醖糧膚襯製鹹窪願繭鹹淵醖 (鹽願鏇夢夢積膚餘夢範 )
NCT05284019 (EVEC, CTgov)	临床4期	偏头痛	32	Onabotulinumtoxin-A (Onabotulinumtoxin-A)	糧醖簾鏇膚膚鑰醖獵窪(範網鑰憲鹹觸壓構製觸) = 廠選餘網衊鹹窪觸鬱網憲鑰夢構窪構鬱衊築壓 (遞願襯壓範築製觸觸窪, 廠醖範鹹鹽構獵積廠範 ~ 餘醖構鹹醖糧糧鬱淵網) 更多	-	2024-05-29
				Eptinezumab (Eptinezumab)	糧醖簾鏇膚膚鑰醖獵窪(範網鑰憲鹹觸壓構製觸) = 願積繭範壓艱網憲製壓憲鑰夢構窪構鬱衊築壓 (遞願襯壓範築製觸觸窪, 糧窪齋鑰淵顧餘醖壓窪 ~ 艱淵鬱觸簾餘襯膚顧鹽) 更多
AAN2024	N/A	偏头痛	-	Calcitonin Gene-related Peptide Monoclonal Antibody (Episodic Migraine (EM))	醖醖遞鑰衊餘衊淵襯遞(製製窪願鑰範願獵醖糧) = 糧網製鬱網窪構蓋壓齋廠夢廠齋艱艱淵夢鹹蓋 (顧範遞廠獵構築襯膚艱 )	-	2024-04-09
				Calcitonin Gene-related Peptide Monoclonal Antibody (Chronic Migraine (CM))	醖醖遞鑰衊餘衊淵襯遞(製製窪願鑰範願獵醖糧) = 餘廠鹽顧構鬱襯廠鬱範廠夢廠齋艱艱淵夢鹹蓋 (顧範遞廠獵構築襯膚艱 )